Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2- Breast Cancer”

564 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 564 results

Large-scale testing (Phase 3)Looking for participantsNCT07281833
What this trial is testing

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

Who this might be right for
Breast CancerHR-positive Breast CancerAdvanced Breast Cancer+2 more
West German Study Group 250
Testing effectiveness (Phase 2)UnknownNCT05400993
What this trial is testing

Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

Who this might be right for
Breast Cancer
Shengjing Hospital 59
Not applicableStudy completedNCT06003114
What this trial is testing

Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

Who this might be right for
Breast Cancer
Pfizer 472
Not applicableStudy completedNCT05853432
What this trial is testing

A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy

Who this might be right for
HR+/HER2- Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals 157
Early research (Phase 1)Looking for participantsNCT06120283
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorAdvanced Breast CancerMetastatic Breast Cancer+6 more
BeOne Medicines 399
Testing effectiveness (Phase 2)Looking for participantsNCT06207734
What this trial is testing

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 120
Testing effectiveness (Phase 2)Looking for participantsNCT06375707
What this trial is testing

Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 144
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Not applicableEnded earlyNCT03786107
What this trial is testing

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Who this might be right for
Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerMetastatic Cervical Cancer
Puma Biotechnology, Inc. 1,583
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Testing effectiveness (Phase 2)Looking for participantsNCT05911958
What this trial is testing

SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Who this might be right for
HER2 Low Breast Carcinoma
Henan Cancer Hospital 66
Large-scale testing (Phase 3)Active Not RecruitingNCT06343948
What this trial is testing

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

Who this might be right for
HR+HER2- Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 383
Not applicableNot Yet RecruitingNCT07190651
What this trial is testing

Development of a New Remote Monitoring Model for Patients With HR+HER2- Breast Cancer in Treatment With CDK4/6 Inhibitors and Hormone Therapy

Who this might be right for
Breast CancerCDK4/6 Inhibitor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 50
Testing effectiveness (Phase 2)UnknownNCT03638648
What this trial is testing

Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 80
Not applicableLooking for participantsNCT07180056
What this trial is testing

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Wenjin Yin 229
Not applicableNot Yet RecruitingNCT07098507
What this trial is testing

De-escalation in Axillary Surgery for Early-stage Breast Cancer

Who this might be right for
Omitting Sentinel Lymph Node Biopsy in Early-stage Breast Cancer
Clinical Hospital Center Rijeka 620
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05986071
What this trial is testing

I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers

Who this might be right for
Breast Cancer
Institut Paoli-Calmettes 57
Not applicableStudy completedNCT04735367
What this trial is testing

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

Who this might be right for
Breast Cancer
Pfizer 42
Testing effectiveness (Phase 2)Looking for participantsNCT04282031
What this trial is testing

BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Who this might be right for
Advanced Solid TumorHR+/HER2- Breast Cancer
Beta Pharma (Suzhou) Co., Ltd. 224
Not applicableStudy completedNCT05141240
What this trial is testing

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 4,650
Load More Results